Pancreatic Cancer Trial, Recruiting NCT07186296 Sponsor: EXoPERT Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07186296
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 45 years or older who have been diagnosed with, or are suspected to have, a primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on scans, blood tests, endoscopy, or tissue/cell findings.
  • People whose blood sample was collected before receiving any systemic or definitive treatment for their cancer.
  • People who are willing and able to give written consent to participate.
  • People who are willing and able to follow the study requirements.

Who may not be able to join:

  • People who have been diagnosed with and treated for any cancer in the 5 years before joining the trial.
  • People who have had surgery, hormone therapy, chemotherapy, or radiotherapy for a recent cancer diagnosis within the past 6 months.
  • People who have previously had a bone marrow transplant, stem cell transplant, or solid organ transplant from another person.
  • People who are currently pregnant or breastfeeding.
  • People who have consented to and received treatment in any other cancer-related clinical trial within the past 6 months.
  • People who are currently receiving active treatment for drug abuse.
  • People who have already received any treatment — such as hormone therapy — related to lung, breast, colorectal, pancreatic, or ovarian nodules before entering the study.
  • Cases where the blood sample collected is not suitable for testing due to issues such as contamination or breakdown of red blood cells (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jonathan Dudley, MD, Johns Hopkins University

Phone: (+82) 02 923 8833

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
EXoPERT
Registry
ClinicalTrials.gov
Start date
9 May 2025
Est. completion
31 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Test Sufficient Samples; Evaluate Performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov